SU1152518A3 - Method of obtaining isoxazole derivatives - Google Patents
Method of obtaining isoxazole derivatives Download PDFInfo
- Publication number
- SU1152518A3 SU1152518A3 SU823414099A SU3414099A SU1152518A3 SU 1152518 A3 SU1152518 A3 SU 1152518A3 SU 823414099 A SU823414099 A SU 823414099A SU 3414099 A SU3414099 A SU 3414099A SU 1152518 A3 SU1152518 A3 SU 1152518A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- methyl
- obtaining
- isoxazole derivatives
- general formula
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДг НЫХ ИЗОКСАЗОЛА общей формулы В С1 . / -CH-jO-NH-C-NHj, П ш где В - С,-С -апкил, отличающийс кем, что соединение общей формулы R С1 кНснгО-Шг , О СО где R имеет указанное значение, подвергают взаимодействию с цианамидом в водной среде при комнатной температуре с последуюврт повышением её до 100.METHOD FOR PRODUCING MANUFACTURING OF ISOXAZOLES of the general formula B C1. / -CH-jO-NH-C-NHj, P w where B is C, -C-papil, characterized by the fact that the compound of the general formula R C 1 kHCN2-Cr, O CO where R has the indicated value, is reacted with cyanamide in water at room temperature followed by an increase to 100.
Description
3 Вычислено, %: С 28,89; Н 4,18; 23,24; С 14,70. Найдено, %: С 29,91; Н. 4,68; N 23,40; се 14,62. Исходный 3-метил-4-хлор-5-аминооксиметилизоксазол может быть получен описанные в примерах 2-4 обрааом . Пример 2. Получение 3-метил-4-галоген-5-бромметилизоксазолпроизводных . 0,1 моль соответствующего 3,5-ди метил-4-галогенизоксазола раствор ю в 150 мл безводного четыреххлористого углерода. После добавки 0,5 г перекиси бензоила раствор нагревают до кипени . К смеси в течение полут ра часов маленькими порци ми добавл ют 0,12 моль N-бромсукцинимида, после чего реакционную смесь кип т следующие 4-5 ч. После охлаждени отфильтровывают вьтавший осадок сук цинимида. Остающийс сиропообразньй 3-метил-4-галоген-5-бромметилизокса зол без дальнейшей очистки можно использовать дальше. Выход 90-100%. Пример 3. Получение производных 3-метил-4-галоген-5-(фталими дооксиметил)-изоксазола. 0,1 моль 3-метил-4-галоген-5-бро метилокеаэала раствор ют в 120 мл безводного диметилформамида. После добавки 0,11 моль М-оксифталамида и 0,11 моль .триэтиламина смесь в те чение 2 ч нагревают на вод ной бане при . Реакционную смесь охлажд ют, разбавл ют холодной водой, выпавший кристаллический осадок отфильтровывают , промывают холодной водой и перекристаллизовьюают. 2-Хлорпроизводные: выход 89%, т.пл. 152-153 0 (этанол). Вычислено, %: С 53,54; Н 3,10, N 9,57; С( 12,11. Найдено, %: С 53,08, Н 2,99 N 9,58; се 12,15. 4-Бромпроизводное: выход 90%, т.пл. 154-156С (смесь этанол-вода) Вычислено, %: С 46,31; Н 2,59, N 8,31; Вг 23,70. Найдено, %: С 47,00-, Н 2,59, N 8,25, Вг 23,67. Пример 4. Получение З-мети 4-галоген-5-аминооксиметилизоксазол гидрохлорида. 0,14 моль 3-метил-4-галоген-5 (фталимидооксиметил)-изоксазола рас твор ют в 500 мл безводного дихлор84 метана или дихлорэтана. После добавки 60 г 98%-ного гидразингидрата смесь перемешивают при комнатной температуре в течение 16-20 ч. Выделившийс фталоилгидразид отфильтровывают , промывают дихлорэтаном, фильтрат объедин ют с промывньми жидкост ми и выпаривают досуха. 0статок раствор ют в 200 мл безводного эфира, эфирный раствор сушат над сульфатом магни , концентрируют примерно на треть и насыщают сухим газообразным хлористым водородом. Выделившийс продукт отфильтровьгеа- ют, промывают эфиром и перекристаллизовывают . 4-Хлорпроизводное: выход 87%, т.пл. 198-200 0 (безводный этанол). Вычислено, %: С 30,17; Н 4,05, N 14,08i С| 17,81; С8- 17,81. Найдено, %: С 30,02; Н 3,99; N 14,06; се 17,77; СГ 17,78, 4-Бромпроизводное: выход 83%, т.пл. 180-182С (безводнм этанол). Вычислено, %: С 24, 66; Н 3,11, N11,50-, С 14,56; Вг 32,80. Найдено, %: С 25,11, Н 3,08, N 11,37; С 14,50, Вг 32,72. Соединени формулы 1 обладают сильньм и относительно длительным понижающим кров ное давление действием . Так, З-метил-4-хлоризоксазол-ил-метиленоксигуанидин вызывает ильное снижение кров ного давлени мышей и кроликов; LDs дл этого оединени составл ет 340,0 мг/кг (внутривенно, на мьш1ах) . У кошек сорокова часть дозы LDgj (8,5 мг/кг ивого веса) З-метил-4-хлоризоксазол-5-илметиленоксигуанидина , внутривенно , снижает кров ное давление на 40%. У анестезированных кошек дес та часть дозы LD5-J, , введенна кишечно, вызывает сильное и длительное снижение кров ного давлени : спуст 30 мин пос е введени кров ное давление на 25%, и спуст 90 мин после введени - на 33% ниже, чем до введени испытуемого соединени . При этом соединение существенно не вли ет на частоту сердечных сокращений . Дес та часть дозы TJiyo L-oi-метилдофа (аналога по действию) при введении кишечно снижает кров ное давление у кроликов спуст 30 мин после введени - на 30%, и спуст 90 мин3 Calculated,%: C 28.89; H 4.18; 23.24; From 14.70. Found,%: C 29.91; N. 4.68; N 23.40; All 14.62. The starting 3-methyl-4-chloro-5-aminooxymethylisoxazole can be prepared as described in Examples 2-4. Example 2. Preparation of 3-methyl-4-halogen-5-bromomethylisoxazole derivatives. 0.1 mol of the corresponding 3,5-di methyl-4-haloisoxazole is dissolved in 150 ml of anhydrous carbon tetrachloride. After the addition of 0.5 g of benzoyl peroxide, the solution is heated to boiling. 0.12 mol of N-bromosuccinimide is added to the mixture in half portions in small portions, after which the reaction mixture is boiled for the next 4-5 hours. After cooling, the resulting succinimide precipitate is filtered off. The remaining syrupy 3-methyl-4-halogen-5-bromomethylisox sol can be used further without further purification. Yield 90-100%. Example 3. Preparation of 3-methyl-4-halogen-5- (phthalimy doxymethyl) -isoxazole derivatives. 0.1 mol of 3-methyl-4-halogen-5-bro of methyl ocaeal is dissolved in 120 ml of anhydrous dimethylformamide. After the addition of 0.11 mol of M-hydroxyphthalamide and 0.11 mol of triethylamine, the mixture is heated for 2 hours in a water bath at. The reaction mixture is cooled, diluted with cold water, the precipitated crystalline precipitate is filtered off, washed with cold water and recrystallized. 2-Chlorine derivatives: yield 89%, so pl. 152-153 0 (ethanol). Calculated,%: C 53.54; H 3.10, N 9.57; C (12.11. Found: C 53.08; H 2.99 N 9.58; ce 12.15. 4-Bromo derivative: yield 90%, mp. 154-156 ° C (ethanol-water mixture) Calculated,%: C, 46.31; H, 2.59, N, 8.31; Br, 23.70; Found,%: C, 47.00; H, 2.59; N, 8.25; Br, 23.67. 4. Preparation of 3-methy 4-halogen-5-aminooxymethylisoxazole hydrochloride. 0.14 mol of 3-methyl-4-halogen-5 (phthalimidoooxymethyl) -isoxazole is dissolved in 500 ml of anhydrous methylene dichloromethane or dichloroethane. After adding 60 g 98. % hydrazine hydrate is stirred at room temperature for 16–20 hours. The phthaloyl hydrazide which is separated out is filtered off, washed with dichloroethane, and the filtrate combined with the washing liquids and evaporated to dryness. The residue is dissolved in 200 ml of anhydrous ether, the ether solution is dried over magnesium sulfate, concentrated to about a third and saturated with dry gaseous hydrogen chloride. The separated product is filtered off, washed with ether and recrystallized. Chlorine derivative: yield 87%, mp 198-200 0 (anhydrous ethanol). Calculated,%: C 30.17; H 4.05, N 14.08i C | 17.81; C8-17.81. Found,%: C 30.02; H 3.99; N 14.06; All 17.77; SG 17.78, 4-Bromo derivative: yield 83%, so pl. 180-182C (anhydrous ethanol). Calculated,%: C 24, 66; H 3.11, N11.50- C 14.56; Br 32.80. Found,%: C 25.11, H 3.08, N 11.37; C 14.50, Br 32.72. The compounds of formula 1 have a strong and relatively long-lasting blood pressure lowering effect. Thus, 3-methyl-4-chloroisoxazole-yl-methylenoxyguanidine causes a decrease in the blood pressure of mice and rabbits; The LDs for this compound are 340.0 mg / kg (intravenously, on the neck). In cats, the fortieth portion of the dose of LDgj (8.5 mg / kg willow weight) Z-methyl-4-chloroisoxazol-5-ylmethylenoxyguanidine, intravenously, reduces blood pressure by 40%. In anesthetized cats, the tenth part of the LD5-J dose, administered enteric, causes a strong and prolonged decrease in blood pressure: after 30 minutes after the introduction of blood pressure by 25%, and after 90 minutes after administration, it is 33% lower than prior to the administration of the test compound. However, the compound does not significantly affect the heart rate. Ten part of the dose of TJiyo L-oi-methyldopa (analogous to the action) with the introduction of enteric decreases blood pressure in rabbits 30 minutes later after administration - by 30%, and 90 minutes later
i11525186i11525186
после введени - на 37%, Это означа-(К-вызванного локальным введением декет , что сила действи производногострана, т.е. соединени формулы Тafter the introduction - by 37%, It means- (K-induced by the local introduction of the deck, that the strength of the effect of the derived country, i.e. the compound of formula
изоксазола и L -о -метилдофа одногообладают ещё и противовоспалительнымisoxazole and L -o-methyldof alone also have anti-inflammatory
пор дка. Преимуществом соединений действием.for now. The advantage of compound action.
формулы 1 вл етс то, что они актив- 5 .Formula 1 is that they are active- 5.
ны при пероральном и внутривенном Таким образом, предлагаемыйin oral and intravenous. Thus, the proposed
введении, а L -о -метилдофа толькоспособ позвол ет получить новые биопри пероральном,логически активные производные р даintroduction, and L -o-methyldopa only allows obtaining new bioprioral, logically active derivatives of the
Кроме того, дес та часть дозыизоксазола, про вл ющие способностьIn addition, the tenth part of the dose of isoxazole, exhibiting the ability
LDjo 3-метил-4-хлоризоксазол-5-илмети-снижать кров ное давление, т.е.LDjo 3-methyl-4-chloroisoxazol-5-ylmeti-lower blood pressure, i.e.
леноксигуанидина, введенна крысам,активностью, ранее неизвестной дл lenoxiguanidine, administered to rats, by activity previously unknown for
вызывает подавление на 32% отека,этого р да соединений.causes a 32% suppression of edema, this row of compounds.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU8080637A HU180567B (en) | 1980-03-19 | 1980-03-19 | Method for producing derivatives of isooxazole |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1152518A3 true SU1152518A3 (en) | 1985-04-23 |
Family
ID=10950573
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU813261940A SU1053750A3 (en) | 1980-03-19 | 1981-03-19 | Process for preparing derivatives of isoxazole |
SU823416146A SU1158044A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining 3-methyl-4-chlorine-5-bromethylaminomethylisoxazole or hydrochloride thereof |
SU823414099A SU1152518A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining isoxazole derivatives |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU813261940A SU1053750A3 (en) | 1980-03-19 | 1981-03-19 | Process for preparing derivatives of isoxazole |
SU823416146A SU1158044A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining 3-methyl-4-chlorine-5-bromethylaminomethylisoxazole or hydrochloride thereof |
Country Status (15)
Country | Link |
---|---|
JP (1) | JPS56158774A (en) |
BE (1) | BE887954A (en) |
CA (1) | CA1163631A (en) |
CH (1) | CH646157A5 (en) |
DE (1) | DE3110817A1 (en) |
DK (3) | DK151012C (en) |
ES (3) | ES501095A0 (en) |
FI (1) | FI70011C (en) |
FR (1) | FR2478634A1 (en) |
GB (1) | GB2075009B (en) |
HU (1) | HU180567B (en) |
IT (1) | IT1211010B (en) |
SE (1) | SE454695B (en) |
SU (3) | SU1053750A3 (en) |
YU (1) | YU42560B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100260A (en) * | 1997-04-21 | 2000-08-08 | Sumitomo Pharmaceutical Company, Limited | Isoxazole derivatives |
ES2248894T3 (en) * | 1997-04-21 | 2006-03-16 | Dainippon Sumitomo Pharma Co., Ltd. | ISOXAZOL DERIVATIVES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL302496A (en) * | 1962-12-22 | |||
US3808221A (en) * | 1971-04-14 | 1974-04-30 | Hoffmann La Roche | Antiandrogenic n-(3,5-dilower alkyl-4-heterocyclic)methyl)phthalimides |
-
1980
- 1980-03-19 HU HU8080637A patent/HU180567B/en not_active IP Right Cessation
-
1981
- 1981-03-16 BE BE1/10179A patent/BE887954A/en not_active IP Right Cessation
- 1981-03-17 YU YU689/81A patent/YU42560B/en unknown
- 1981-03-17 SE SE8101703A patent/SE454695B/en not_active IP Right Cessation
- 1981-03-18 GB GB8108545A patent/GB2075009B/en not_active Expired
- 1981-03-18 ES ES501095A patent/ES501095A0/en active Granted
- 1981-03-18 FR FR8105378A patent/FR2478634A1/en active Granted
- 1981-03-18 DK DK122581A patent/DK151012C/en not_active IP Right Cessation
- 1981-03-18 IT IT8120395A patent/IT1211010B/en active
- 1981-03-18 CH CH182981A patent/CH646157A5/en not_active IP Right Cessation
- 1981-03-18 FI FI810838A patent/FI70011C/en not_active IP Right Cessation
- 1981-03-19 DE DE19813110817 patent/DE3110817A1/en not_active Withdrawn
- 1981-03-19 JP JP4023281A patent/JPS56158774A/en active Pending
- 1981-03-19 SU SU813261940A patent/SU1053750A3/en active
- 1981-03-19 CA CA000373380A patent/CA1163631A/en not_active Expired
-
1982
- 1982-04-01 SU SU823416146A patent/SU1158044A3/en active
- 1982-04-01 SU SU823414099A patent/SU1152518A3/en active
- 1982-04-16 ES ES511894A patent/ES8401758A1/en not_active Expired
- 1982-04-16 ES ES511895A patent/ES8305340A1/en not_active Expired
-
1987
- 1987-01-16 DK DK023187A patent/DK153549C/en not_active IP Right Cessation
- 1987-01-16 DK DK023087A patent/DK151959C/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
1. Патент US № 3804898, кл.-С 07 С 129/00, опублик. 1974. 2.Патент FR № 2419289, кл. С 07 D 261/08, опублик. 1979 3.Машковский М.Д. Лекарственные средства, т.1, М., Медицина, 1978, с. 275. * |
Also Published As
Publication number | Publication date |
---|---|
GB2075009B (en) | 1983-11-30 |
CA1163631A (en) | 1984-03-13 |
IT1211010B (en) | 1989-09-29 |
ES511894A0 (en) | 1984-01-01 |
ES8302674A1 (en) | 1983-02-16 |
GB2075009A (en) | 1981-11-11 |
DK153549B (en) | 1988-07-25 |
DK151959C (en) | 1988-07-11 |
ES511895A0 (en) | 1983-05-01 |
ES501095A0 (en) | 1983-02-16 |
DE3110817A1 (en) | 1982-03-04 |
BE887954A (en) | 1981-09-16 |
SE8101703L (en) | 1981-09-20 |
IT8120395A0 (en) | 1981-03-18 |
ES8401758A1 (en) | 1984-01-01 |
HU180567B (en) | 1983-03-28 |
DK23087A (en) | 1987-01-16 |
FI810838L (en) | 1981-09-20 |
YU68981A (en) | 1983-10-31 |
DK151959B (en) | 1988-01-18 |
SU1158044A3 (en) | 1985-05-23 |
DK23187A (en) | 1987-01-16 |
YU42560B (en) | 1988-10-31 |
CH646157A5 (en) | 1984-11-15 |
DK151012B (en) | 1987-10-12 |
SE454695B (en) | 1988-05-24 |
FR2478634A1 (en) | 1981-09-25 |
FR2478634B1 (en) | 1983-11-10 |
ES8305340A1 (en) | 1983-05-01 |
FI70011C (en) | 1986-09-12 |
DK153549C (en) | 1988-12-05 |
DK122581A (en) | 1981-09-20 |
DK151012C (en) | 1988-07-04 |
SU1053750A3 (en) | 1983-11-07 |
JPS56158774A (en) | 1981-12-07 |
FI70011B (en) | 1986-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Petersen et al. | Synthesis and hypotensive activity of N-alkyl-N''-cyano-N'-pyridylguanidines | |
Sircar et al. | Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4, 5-dihydro-6-[4-(H-imidazol-1-yl) phenyl]-3 (2H)-pyridazinones: a new class of positive inotropic agents | |
EP0175363B1 (en) | 4,5-dihydro-3(2h)-pyridazinones, process for their preparation and their use | |
DE2559509A1 (en) | BENZCYLOAMIDE DERIVATIVES AND METHODS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PRODUCTS WHICH CONTAIN THEY | |
US3047462A (en) | Quinazolone anti-inflammatory composition | |
EP0327800B1 (en) | 6-phenyldihydro-3(2h)-pyridazinones, process for their preparation and medicines containing these compounds | |
US4704387A (en) | N-benzyl, phenethyl, methoxyethyl or allyl substituted benzylphthalazinones having antiallergic and antihistamine action | |
EP0059356B1 (en) | Substituted 3-amino-sydnonimine, process for their preparation and their application | |
DD152934A5 (en) | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-AMINO-SYNDNONIMINES | |
SU1152518A3 (en) | Method of obtaining isoxazole derivatives | |
PT84923B (en) | A process for the preparation of 1- (HYDROXYSTIRYL) -5H-2,3-BENZODIAZEPINE DERIVATIVES AND OF THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
US3449355A (en) | 2-((3,4-dihalophenoxy)methyl)-2-imidazoline | |
EP0327808B1 (en) | Substituted 3-aminosydnonimines, process for their preparation and their use | |
US4006232A (en) | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | |
Olivard et al. | Metabolic and photochemical hydroxylation of 5-nitro-2-furancarboxaldehyde derivatives | |
CH407088A (en) | Process for the preparation of 4-halo-3-sulfamoyl-benzoic acid derivatives | |
US3449357A (en) | 2-((2,6-substituted)phenoxymethyl)-2-imidazolines | |
US4137321A (en) | Isoxazole carboxamides of m-aminotetramisole as anthelmintics | |
US3449356A (en) | 2-((halophenoxy)methyl)-2-imidazolines | |
US4530843A (en) | Isoindole amidoxime derivatives | |
EP0064294A1 (en) | 1,5-Substituted isoquinoline derivatives | |
US3993643A (en) | N-substituted 2-[2-(5-nitro-2-furyl) vinyl]imidazoles | |
EP0429751B1 (en) | Substituted 3-amino-sydnonimines, process for their preparation and their use | |
US3541145A (en) | Herbicide compositions | |
HU201910B (en) | Process for producing new n-(1h-indol-4-yl)-benzamide derivatives and pharmaceutical compositions containing them |